Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 3Head and Neck Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Erectile Dysfunction 2Carcinoma 2Adenocarcinoma 2Urogenital Neoplasms 1Pyridoxine-dependent epilepsy 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Multiple Myeloma 1Mouth Neoplasms 1Glioblastoma 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Astrocytoma 1Abdominal Cancer 1

Interventions

Acupuncture Therapy 10Exercise 6Cryotherapy 6Paclitaxel 5Glutamine 4Surveys and Questionnaires 3Duloxetine Hydrochloride 3Dexamethasone 3Bortezomib 3Acetylcysteine 3Thioctic Acid 2Tablets 2Sodium Chloride 2Saline Solution 2Physical Therapy Modalities 2Low-Level Light Therapy 2Fish Oils 2Fatty Acids, Omega-3 2ziconotide 1pembrolizumab 1nicotinamide-beta-riboside 1glutamic acid diethyl ester 1enfortumab vedotin 1Yoga 1XELOX 1Vitamin D 1Vitamin B Complex 1Vitamin B 6 1Vitamin B 12 1Ultrasonic Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Peripheral Nervous System Diseases × Tadalafil × Clear all
NCT07333976 2026-01-12

o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

Tri-Service General Hospital

Phase 2 Completed
90 enrolled

Peripheral Nervous System Diseases, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡